ライフサイエンスコーパス: acetylgalactosamine

1 osamine to generate undecaprenyl phosphate-N-acetylgalactosamine.

2 actose, UDP- N-acetylglucosamine, and UDP- N-acetylgalactosamine.

3 characterized by a terminal or sialylated N-acetylgalactosamine.

4 glycan ligands that include galactose and N-acetylgalactosamine.

5 hree rhamnose residues and a protein-bound N-acetylgalactosamine.

6 discriminated for N-acetylglucosamine and N-acetylgalactosamine.

7 with regard to both UDP-galactose and UDP-N-acetylgalactosamine.

8 plete loss of activity with respect to UDP-N-acetylgalactosamine.

9 cific lectin and shows little affinity for N-acetylgalactosamine.

10 substrates UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine.

11 lucose, galactose, N-acetylglucosamine and N-acetylgalactosamine.

12 -5'-[P1-32P]triphosphate, an analog of UDP-N-acetylgalactosamine.

13 e and partially reduced with regard to UDP-N-acetylgalactosamine.

14 no sugars, UDP N-acetylglucosamine and UDP N-acetylgalactosamine.

15 acetylglucosamine, mannose, galactose, and N-acetylgalactosamine.

16 ns following binding to terminal galactose/N-acetylgalactosamine.

17 linking the peptide backbone to the sugar N-acetylgalactosamine.

18 atives of 2,4-diacetamidobacillosamine and N-acetylgalactosamine.

19 d was inhibited by N-acetylglucosamine and N-acetylgalactosamine.

20 rate UDP-N-acetylglucosamine or isomer UDP-N-acetylgalactosamine.

21 ), N-acetylglucosamine (2.27 nmol/mg), and N-acetylgalactosamine (0.652 nmol/mg).

22 eat unit synthesis, likely by transferring N-acetylgalactosamine-1-P to undecaprenyl-phosphate.

23 Eight N-acetylglucosamine-1-phosphate and N-acetylgalactosamine-1-phosphate analogs have been synthe

24 eficient activity of arylsulfatase B (ASB; N-acetylgalactosamine 4-sulfatase) and the subsequent accu

25 iency of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase), either innate or acqui

26 -acetylglucosamine analog by the epimerase N-acetylgalactosamine-4-epimerase (GALE) like conventional

27 matan sulfate preparations, we showed that N-acetylgalactosamine-4-O-sulfate residues are required fo

28 CHST8 encodes a Golgi transmembrane N-acetylgalactosamine-4-O-sulfotransferase (GalNAc4-ST1),

29 ntity with HNK-1 sulfotransferase (21.4%), N-acetylgalactosamine-4-O-sulfotransferase 1 (GalNAc-4-ST1

30 sulfotransferase 1 (GalNAc-4-ST1) (24.7%), N-acetylgalactosamine-4-O-sulfotransferase 2 (GalNAc-4-ST2

31 We have identified and characterized an N-acetylgalactosamine-4-O-sulfotransferase designated derm

32 The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB))

33 -l-iduronidase, iduronate-2-sulfatase, and N-acetylgalactosamine-4-sulfatase that are used for newbor

34 ombinant human (rh) Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) markedly reduced the vo

35 ivity of the enzyme arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase).

36 Arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB) removes 4-sulfate

37 al exohydrolase, cleaving sulfate from the N-acetylgalactosamine-4-sulfate (GalNAc-4S) residue at the

38 We have cloned the N-acetylgalactosamine-4-sulfotransferase (GalNAc-4-ST1, Ge

39 samine (4FGlcNAc) and UDP-4-deoxy-4-fluoro-N-acetylgalactosamine (4FGalNAc), were prepared using both

40 tosamine-6-sulfatase (GALNS, also known as N-acetylgalactosamine-6-sulfatase and GalN6S; E.C. 3.1.6.4

41 s an autosomal recessive disease caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficien

42 es, including Morquio A syndrome caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficien

43 cessive disorder caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), a lysos

44 cessive disorder caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leading

45 in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

46 e disorder (LSD) caused by a deficiency of N-acetylgalactosamine-6-sulfate sulfatase enzyme.

47 glucose, 3-deoxy-D-manno-octulosonic acid, N-acetylgalactosamine, 8-epi-legionaminic acid, phosphate,

48 nsist mostly of core 1 alpha2,6 sialylated N-acetylgalactosamine, a configuration suspected to preven

49 vivo, AIMers targeted to hepatocytes with N-acetylgalactosamine achieve up to 50% editing with no by

50 en-Friedenreich antigen (galactose beta1-3 N-acetylgalactosamine alpha-), we have found that this lec

51 This truncated antigen has the sugar N-acetylgalactosamine alpha-linked to either a serine or t

52 on the presence of multiple O-linked alpha-N-acetylgalactosamine (alpha-GalNAc) determinants.

53 agglutin (HPA)) with specificity for alpha-N-acetylgalactosamine (alpha-GalNAc), an epitope displayed

54 use have been overcome by conjugation with N-acetylgalactosamine, an adduct that targets their delive

55 The sulfate portions of 4-sulfated-N-acetylgalactosamine and an unidentified ligand found in

56 rssman (Fs) antigen terminates with alpha3-N-acetylgalactosamine and can be used by pathogens as a ho

57 sponsible for the uptake and metabolism of N-acetylgalactosamine and galactosamine in Escherichia col

58 use DBP carries a disaccharide composed of N-acetylgalactosamine and galactose.

59 eful for the synthesis of [32P]5-azido-UDP-N-acetylgalactosamine and high-specific-activity [3H] or [

60 ly acetylated 1-->4 glycosidic linkages of N-acetylgalactosamine and N-acetylglucosamine.

61 Ac translocator has lower affinity for UDP-N-acetylgalactosamine and UDP-glucose than for its cognate

62 er can catalyze the interconversion of UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine while th

63 art, mammalian GALE also interconverts UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

64 rconverts a larger pair of substrates: UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

65 -galactose and UDP-glucose, as well as UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine.

66 l-fucose, d-mannose, N-acetylglucosamine, N-acetylgalactosamine, and galactose).

67 eric monosaccharides, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylmannosamine.

68 ining the addition of phosphoethanolamine, N-acetylgalactosamine, and N-acetylneuraminic acid.

69 finity purified on immobilized lactose and N-acetylgalactosamine, and N-glycosylated but not glycosid

70 SQV-7 transported UDP-glucuronic acid, UDP-N-acetylgalactosamine, and UDP-galactose (Gal) in a temper

71 e form of LD, express a unique glycan with N-acetylgalactosamine as a terminal sugar.

72 -acetylglucosamine or uridine 5'-diphospho-N-acetylgalactosamine as substrates but will accept uridin

73 owever, the enzyme preferentially utilized N-acetylgalactosamine as the donor for all three acceptors

74 that bear uronic acid linked to unsulfated N-acetylgalactosamine as the initial disaccharide in the C

75 crophage activating factor, a protein with N-acetylgalactosamine as the remaining sugar moiety.

76 ein (DBP) to yield the MAF, a protein with N-acetylgalactosamine as the remaining sugar.

77 including fucose, N-acetylglucosamine, and N-acetylgalactosamine as well as the yeast polysaccharide

78 Cys-MR alone and complexed with 4-sulfated-N-acetylgalactosamine at 1.7 and 2.2 A resolution, respect

79 Phosphorylated O-mannosyl trisaccharide [N-acetylgalactosamine-beta3-N-acetylglucosamine-beta4-(pho

80 st that it is a good model for the natural N-acetylgalactosamine binding site of the asialoglycoprote

81 cleaves cell surface galactose-binding or N-acetylgalactosamine-binding (Gal/Gal-NAc) lectins.

82 ansferase activity from UDP-galactose onto N-acetylgalactosamine but with a low efficiency.

83 rotein reporter showed that it transferred N-acetylgalactosamine, but no detectable galactose or N-ac

84 howed that the purified enzyme transferred N-acetylgalactosamine, but no detectable galactose or N-ac

85 ise fashion beginning with the addition of N-acetylgalactosamine by the enzyme N-acetylgalactosaminyl

86 D displays 40-fold preferential binding to N-acetylgalactosamine compared with galactose, making it a

87 fold increase in the relative affinity for N-acetylgalactosamine compared with galactose.

88 n family, displays preferential binding to N-acetylgalactosamine compared with galactose.

89 oparticle formulation or as a triantennary N-acetylgalactosamine conjugate in cells and in mice.

90 g or 4 mg/kg RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated anti-miR-122 oligonucleot

91 ngle dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that anta

92 A fully phosphorothioated, N-acetylgalactosamine-conjugated 16-mer antisense ON (full

93 Treatment with RG-101, an N-acetylgalactosamine-conjugated anti-microRNA-122 oligonu

94 Olezarsen is an N-acetylgalactosamine-conjugated antisense oligonucleotide

95 Cardiovascular outcome trials with N-acetylgalactosamine-conjugated RNA-targeting drugs are o

96 n the guide or passenger strand of the tri-N-acetylgalactosamine-conjugated siRNA targeting mouse Ttr

97 irst-in-class, synthetic, double-stranded, N-acetylgalactosamine-conjugated small interfering RNA (si

98 Givosiran is a subcutaneously administered N-acetylgalactosamine-conjugated small interfering RNA aga

99 to evaluate the impact of solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA dev

100 ining siRNAs were prepared as triantennary N-acetylgalactosamine conjugates and were tested in cultur

101 l chemistry and liver targeting enabled by N-acetylgalactosamine conjugation make this ASO highly pot

102 followed 24 hours later by a biotinylated N-acetylgalactosamine-containing "clearing agent" and fina

103 ministered sequentially with a dendrimeric N-acetylgalactosamine-containing clearing agent and radiol

104 reptavidin (SA) conjugates, followed by an N-acetylgalactosamine dendrimeric clearing agent and radio

105 lycan consisting of repeating uronic acid, N-acetylgalactosamine disaccharide units {[HexAbeta/alpha(

106 sporter of UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine encoded by the Caenorhabditis elegan

107 f a melittin-derived peptide conjugated to N-acetylgalactosamine for hepatocyte targeting and endosom

108 first enzyme required for biosynthesis of N-acetylgalactosamine, for the major cyst wall polysacchar

109 e Fml adhesin FmlH binds galactose beta1-3 N-acetylgalactosamine found in core-1 and -2 O-glycans.

110 s involving lipid nanoparticle carriers or N-acetylgalactosamine fragments.

111 ansfer reaction of N-acetylglucosamine and N-acetylgalactosamine from the respective UDP-sugars to th

112 lycans by catalyzing the transfer of alpha-N-acetylgalactosamine from UDP-GalNAc to Ser or Thr residu

113 parvum sporozoites to the sugar, galactose-N-acetylgalactosamine (Gal/GalNAc), and to bovine mucin re

114 The glycan sequence N-acetylgalactosamine, galactose, and sialic acid was cons

115 ne DBP carries a trisaccharide composed of N-acetylgalactosamine, galactose, and sialic acid, whereas

116 glycosidase that cleaves galactose beta1-3 N-acetylgalactosamine (Galbeta1-3GalNAc) from core-1 O-lin

117 tigen is a disaccharide, galactose beta1-3 N-acetylgalactosamine (Galbeta1-3GalNAc), expressed on the

118 WbiP could readily glycosylate a series of N-acetylgalactosamine (GalNAc) analogues with alpha-substi

119 roduce a polysaccharide capsule containing N-acetylgalactosamine (GalNAc) and beta-3-deoxy-d-manno-oc

120 t tx5a contains a disaccharide composed of N-acetylgalactosamine (GalNAc) and galactose (Gal), but th

121 residues: one fucose (Fuc) and two each of N-acetylgalactosamine (GalNAc) and galactose (Gal).

122 e production of both UDP-galactose and UDP-N-acetylgalactosamine (GalNAc) and is required for the pro

123 two constituents of cell-surface glycans, N-acetylgalactosamine (GalNAc) and sialic acid, with 10-20

124 ne reproductive tract mucins, and terminal N-acetylgalactosamine (GalNAc) and sulfated carbohydrates

125 Chemical analyses confirmed the loss of N-acetylgalactosamine (GalNAc) and the presence of NeuNAc

126 l interfering RNAs conjugated to trivalent N-acetylgalactosamine (GalNAc) are clinically validated dr

127 his protocol, N-acetylglucosamine (GlcNAc)/N-acetylgalactosamine (GalNAc) are phosphorylated by N-ace

128 N-Acetylgalactosamine (GalNAc) conjugated short interferin

129 independent pathways, and GALNTL5 binds to N-acetylgalactosamine (GalNAc) distributed on the UTJ and

130 oglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delive

131 osynthesis is initiated by the transfer of N-acetylgalactosamine (GalNAc) from a nucleotide sugar don

132 occurring glycoconjugate motifs containing N-acetylgalactosamine (GalNAc) from the cheaper and commer

133 ific for cancer-relevant Ser/Thr(O)-linked N-acetylgalactosamine (GalNAc) glycosylation.

134 opolymer: chitin in Entamoeba and a unique N-acetylgalactosamine (GalNAc) homopolymer in Giardia.

135 We found that not only galactose but also N-acetylgalactosamine (GalNAc) is an efficient competitor

136 e strand functionalized with the trivalent N-acetylgalactosamine (GalNAc) ligand and cyclized using '

137 r) gene and were conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted deliver

138 and metabolic stability, conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted deliver

139 (siRNA) that is conjugated to a trivalent N-acetylgalactosamine (GalNAc) ligand.

140 Tn-antigen (Tn), a single N-acetylgalactosamine (GalNAc) monosaccharide attached to

141 recognizes the sugars galactose (Gal) and N-acetylgalactosamine (GalNAc) on the surface of host cell

142 , like FS, catalyze the addition of either N-acetylgalactosamine (GalNAc) or galactose (Gal) in alpha

143 1-->3 glycosidic linkage to the core alpha-N-acetylgalactosamine (GalNAc) residue.

144 ed to the BclA protein backbone through an N-acetylgalactosamine (GalNAc) residue.

145 ining IgA1 and IgG antibodies specific for N-acetylgalactosamine (GalNAc) residues in O-linked glycan

146 s 61% (range, 12-95%) of the peptide alpha-N-acetylgalactosamine (GalNAc) residues to be substituted

147 complexed with beta-methyl galactoside and N-acetylgalactosamine (GalNAc) reveal that as with wild-ty

148 ve transfers of glucoronic acid (GlcA) and N-acetylgalactosamine (GalNAc) to elongate a chain consist

149 lycosylation by catalyzing the transfer of N-acetylgalactosamine (GalNAc) to Ser or Thr on a protein

150 glycosylation is initiated by polypeptide N-acetylgalactosamine (GalNAc) transferase (ppGalNAcT) act

151 Our knowledge of the O-glycoproteome [N-acetylgalactosamine (GalNAc) type] is highly limited.

152 calibacterium prausnitzii that harbours an N-acetylgalactosamine (GalNAc) utilization gene cluster is

153 e (GlcNAc), galactose (Gal), xylose (Xyl), N-acetylgalactosamine (GalNAc), and glucose (Glc), using g

154 glycosylation containing galactose (Gal), N-acetylgalactosamine (GalNAc), and sialic acid.

155 nopeptidase N is specifically inhibited by N-acetylgalactosamine (GalNAc), suggesting that this toxin

156 ds of small interfering RNA (siRNA) to tri-N-acetylgalactosamine (GalNAc), the ligand for a hepatocyt

157 , as demonstrated by the implementation of N-acetylgalactosamine (GalNAc)-conjugated ASOs for Asialog

158 silencing in the context of the trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNA in mice re

159 One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the re

160 t with highly potent and durable trivalent N-acetylgalactosamine (GalNAc)-conjugated small interferin

161 this study, we investigated the effects of N-acetylgalactosamine (GalNAc)-conjugated small interferin

162 Certain lectins recognize the terminal N-acetylgalactosamine (GalNAc)-containing O-glycans on Gal

163 or facile synthesis of novel and divergent N-acetylgalactosamine (GalNAc)-glycosides and derivatives

164 nucleotide (ASO) and a hepatocyte-specific N-acetylgalactosamine (GalNAc)-modified siRNA, both of whi

165 Focusing on liver-targeted N-acetylgalactosamine (GalNAc)-siRNA conjugates, the prima

166 ngiensis strains) lacked Gal and contained N-acetylgalactosamine (GalNAc).

167 ides that are modified with beta1,4-linked N-acetylgalactosamine (GalNAc).

168 inked galactose and partially deacetylated N-acetylgalactosamine (GalNAc).

169 mucin O-glycoproteins and their core sugar N-acetylgalactosamine (GalNAc).

170 mily of uridine 5'-diphosphate (UDP)-alpha-N-acetylgalactosamine (GalNAc):polypeptide N-acetylgalacto

171 oteins bearing terminal galactose (Gal) or N-acetylgalactosamine (GalNAc); however, endogenous ligand

172 containing O-glycans comprised of a single N-acetylgalactosamine (GalNAc, known as Tn antigen) rather

173 Mucin-type (N-acetylgalactosamine [GalNAc]-type) O-glycosylation is fo

174 A series of sialyl fucosyl poly-N-acetylgalactosamine gangliosides without the sialyl-Le e

175 oboside or P antigen is synthesized by UDP-N-acetylgalactosamine:globotriaosyl-ceramide 3-beta-N-acet

176 d group criteria and is synthesized by UDP-N-acetylgalactosamine: globotriaosylceramide 3-beta-N-acet

177 egionaminyltransferase selective for alpha-N-acetylgalactosamine-glycoside (GalNAcalphaOR) acceptors.

178 he gene for GM2/GD2 synthase [GalNAcT (UDP-N-acetylgalactosamine:GM3/GD3 beta-1,4-N-acetylgalactosami

179 h, galactosamine, N-acetylglucosamine, and N-acetylgalactosamine had no significant effect on the par

180 n, a fourth region likely to interact with N-acetylgalactosamine has been identified and probed by si

181 structural basis for selective binding to N-acetylgalactosamine has been investigated.

182 to be important in preferential binding to N-acetylgalactosamine have been inserted into the homologo

183 ends on the correct spacer design and that N-acetylgalactosamine improves targeting properties in viv

184 transferred sulfate to the C-4 position of N-acetylgalactosamine in chondroitin and desulfated dermat

185 a binding pocket for the 2-substituent of N-acetylgalactosamine in the hepatic asialoglycoprotein re

186 HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared wi

187 hifts of amide signals from (15)N-containing acetylgalactosamines in CSs are shown to be quite sensit

188 cetylhexosamine (HexNAc), either GlcNAc or N-acetylgalactosamine, in the terminal position or, altern

189 lycosylated CD44 enhanced binding; and (d) N-acetylgalactosamine incorporation into non-N-linked glyc

190 is completely inhibited in the presence of N-acetylgalactosamine, indicating loss of domain III bindi

191 ins was identified as the 170-kD galactose/N-acetylgalactosamine-inhibitable lectin (Gal/GalNAc) usin

192 ot galactosamine, N-acetylglucosamine, and N-acetylgalactosamine inhibited the growth of the parasite

193 diate, and light subunits of the galactose-N-acetylgalactosamine-inhibitible lectin, an important cel

194 changed to valine, loss in selectivity for N-acetylgalactosamine is observed.

195 UDP-N-[1-14C]acetylgalactosamine is prepared by acetylation of UDP-ga

196 residues in combination with 4-O-sulfated N-acetylgalactosamine is sufficient for high affinity bind

197 y yeast hexokinase, homoserine kinase, and N-acetylgalactosamine kinase (obtained by comparison of th

198 transition state were 2.1 x 10(-16) m for N-acetylgalactosamine kinase, 7.4 x 10(-17) m for homoseri

199 using 5-azido-UTP, [gamma-32P]ATP, porcine N-acetylgalactosamine kinase, and Escherichia coli UDP-N-a

200 -acetylglucosamine and uridine diphosphate N-acetylgalactosamine, leading to the synthesis of epimeri

201 Fecal anti-galactose/N-acetylgalactosamine lectin immunoglobulin A was associat

202 metabolically stable siRNAs combined with N-acetylgalactosamine ligands for conjugate-based liver de

203 st adenocarcinomas, Tn antigen, comprising N-acetylgalactosamine linked to serine or threonine, is ov

204 cible nitric oxide synthase, and galactose/N-acetylgalactosamine macrophage lectin, as well as TGF-be

205 NAc unit, suggesting that 4-O-sulfation at N-acetylgalactosamine may precede epimerization of glucuro

206 nitiates docking through recognition of an N-acetylgalactosamine moiety on L. dispar APN.

207 galactose, glucose, sialic acid, mannose, N-acetylgalactosamine, N-acetylglucosamine, and fucose.

208 with the terminal galactose replaced with N-acetylgalactosamine (NHAc-Pk).

209 lglucosamine (O-GlcNAc) and O-linked alpha-N-acetylgalactosamine (O-GalNAc) (the Tn antigen), in whic

210 -glycans in the mammalian brain, which are N-acetylgalactosamine (O-GalNAc) linked.

211 ion, O-linked mannose (O-Man) and O-linked N-acetylgalactosamine (O-GalNAc), in its highly conserved

212 er/Thr-O-GlcNAc, alpha-linked Ser-O-linked N-acetylgalactosamine (O-GalNAc), or N-linked oligosacchar

213 mucin-related O-linked glycopeptide, alpha-N-acetylgalactosamine-O-serine/threonine (Tn), which is hi

214 interaction enhances the deacetylation of N-acetylgalactosamine oligosaccharides.

215 nalogue PPA15(T7), glycosylated with alpha-N-acetylgalactosamine on Thr7, were prepared and investiga

216 nt have lost the ability to utilize either N-acetylgalactosamine or galactosamine as sole sources of

217 s had elevated activity in the presence of N-acetylgalactosamine or galactosamine, were regulated in

218 Enzymatic removal of the terminal N-acetylgalactosamine or galactose of A- or B-antigens, re

219 binds to glycoproteins expressing terminal N-acetylgalactosamine or galactose residues.

220 ns modified with polymeric forms of either N-acetylgalactosamine or N-acetylglucosamine target hepati

221 They usually link to galactose, N-acetylgalactosamine, or other Sia residues, forming liga

222 or (a structure terminated with galactose, N-acetylgalactosamine, or sialic acid).

223 mine but not by galactose, xylose, fucose, N-acetylgalactosamine, or sialic acid-containing glycoprot

224 tions appear to produce the preference for N-acetylgalactosamine over galactose and are also likely t

225 essential for establishing selectivity for N-acetylgalactosamine over galactose.

226 suppressed by a polymer glycosylated with N-acetylgalactosamine (pGal) and conjugated to the antigen

227 he partially deacetylated alpha-1,4 linked N-acetylgalactosamine polymer, Pel.

228 The UDP-N-acetylgalactosamine polypeptide:N-acetylgalactosaminyltr

229 y distinct recombinant uridine diphosphate-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltr

230 ides over Ser peptides for the porcine UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltr

231 e ability to synthesize polyprenyl-phospho-N-acetylgalactosamine (polyprenyl-P-GalNAc) from polypreny

232 n complex with the N-acetylglucosamine and N-acetylgalactosamine products of catalysis and in complex

233 te the existence of another galactose- and N-acetylgalactosamine-recognizing lectin distinct from mMG

234 play stronger binding to galactosamine and N-acetylgalactosamine relative to d-galactose.

235 inked oligosaccharides containing terminal N-acetylgalactosamine required for [125I]Cry1Ac binding in

236 the core of these glycans is frequently an N-acetylgalactosamine residue that is alpha-linked to seri

237 e interaction of the peptide and the first N-acetylgalactosamine residue.

238 exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and glyc

239 Each cleaved nonreducing alpha(1-->3)-N-acetylgalactosamine residues from human blood group A an

240 nt in patients with IgAN, leaving terminal N-acetylgalactosamine residues in the hinge region exposed

241 eptor binds oligosaccharides with terminal N-acetylgalactosamine residues more tightly than ligands w

242 of bulky substituents to the reducing end N-acetylgalactosamine residues of C4S dodecasaccharide had

243 ype lectin 2 receptor on microglia through N-acetylgalactosamine residues, leading to lethal neurodeg

244 e epitope recognized by 4E9 contains alpha-N-acetylgalactosamine residues, which are present in a muc

245 s a result of the presence of alpha-linked N-acetylgalactosamine residues.

246 r determination of the sulfate position on N-acetylgalactosamine residues.

247 eir glycan components contain alpha-linked N-acetylgalactosamine residues.

248 hydrate-recognition domain in complex with N-acetylgalactosamine reveals a direct interaction between

249 port that metabolic cross-talk between the N-acetylgalactosamine salvage and O-GlcNAcylation pathways

250 good as or better than that of the parent N-acetylgalactosamine, showing that modification on either

251 N -acetylgalactosamine si Cnnm4 therapy boosts the repair p

252 or the rat Kupffer cell lectin (fucose and N-acetylgalactosamine specific) adhered specifically to gl

253 erase was significantly lower, and that of N-acetylgalactosamine-specific alpha2,6-sialyltransferase

254 syltransferase activity and an increase in N-acetylgalactosamine-specific alpha2,6-sialyltransferase

255 transferase or a terminal sialic acid by a N-acetylgalactosamine-specific alpha2,6-sialyltransferase.

256 own as the mouse macrophage galactose- and N-acetylgalactosamine-specific lectin (mMGL).

257 ither patent or latent reactivity with the N-acetylgalactosamine-specific lectin Vicia villosa agglut

258 e neutralizing effect of the MAb and alpha-N-acetylgalactosamine-specific lectins strongly implicate

259 drate units that terminate with a sulfated N-acetylgalactosamine structure (GalNAc-4-SO(4)) that medi

260 ific for either N-acetylneuraminic acid or N-acetylgalactosamine, suggesting that it was composed of

261 lycan consisting of repeating uronic acid, N-acetylgalactosamine sulfate disaccharide units [-UroA(be

262 rophoresis analysis demonstrated increased N-acetylgalactosamine sulfation at both 4- and 6-carbons.

263 ctins specifically recognize galactose- or N-acetylgalactosamine-terminated oligosaccharides.

264 tal structure of the modified CRD bound to N-acetylgalactosamine, the histidine (His(202)) contacts t

265 r the discrimination between galactose and N-acetylgalactosamine, the substrate transferred by GTA.

266 s convert added peracetylated benzyl-alpha-N-acetylgalactosamine to a large variety of modified O-gly

267 ages joining either N-acetylglucosamine or N-acetylgalactosamine to a wide variety of aglycon residue

268 structures showed N-acetylglucosamine and N-acetylgalactosamine to be recognized via identical sets

269 ferred galactose, N-acetylglucosamine, and N-acetylgalactosamine to carbohydrate, glycoprotein, and g

270 ensation of undecaprenyl phosphate and UDP-N-acetylgalactosamine to generate undecaprenyl phosphate-N

271 rabinose, fucose, methyl galacturonate and N-acetylgalactosamine to give the corresponding peracetyla

272 nant EXTL2 showed weak ability to transfer N-acetylgalactosamine to heparan sulfate precursor molecul

273 re chemically stabilized and conjugated to N-acetylgalactosamine to increase liver uptake.

274 dification of glycans by beta4 addition of N-acetylgalactosamine to N-acetylglucosamine with formatio

275 o incorporation of N-acetylglucosamine and N-acetylgalactosamine to oligosaccharide acceptors resembl

276 inst Anln messenger RNA were conjugated to N-acetylgalactosamine to reduce toxicity and increase hepa

277 The addition of N-acetylgalactosamine to Ser71, Thr72, Thr75, and Thr139 l

278 U3 also catalyzes the epimerization of UDP-N-acetylgalactosamine to UDP-N-acetylglucosamine, and the

279 e acetyl group from undecaprenyl phosphate-N-acetylgalactosamine to yield undecaprenyl phosphate-beta

280 ynthase K4CP catalyzes glucuronic acid and N-acetylgalactosamine transfer activities and polymerizes

281 sequence abolishes glucuronic acid but not N-acetylgalactosamine transfer activity in K4CP.

282 The polypeptide N-acetylgalactosamine transferase-1 (ppGalNAcT-1) initiate

283 lasmic reticulum relocation of polypeptide N-acetylgalactosamine-transferases (GalNAc-Ts) drives high

284 purified the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter.

285 We conjugated binders to a triantenerrary N-acetylgalactosamine (tri-GalNAc) motif that engages ASGP

286 Here we show that the N-acetylgalactosamine-type O-glycosylation enzyme GALNT11

287 ein, shows UDP-GlcNAcA 4-epimerase and UDP-N-acetylgalactosamine (UDP-GalNAc) 4-epimerase activities.

288 P-N-acetylglucosamine (UDP-GlcNAc) and UDP-N-acetylgalactosamine (UDP-GalNAc) transport in Arabidopsi

289 ratio of UDP-GlcNAc to uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc), irrespective of the in

290 to complex gangliosides bearing the sialyl N-acetylgalactosamine unit.

291 type transporter, whereas transport of UDP-N-acetylgalactosamine was decreased by 85-90%, resulting i

292 TTST(GalNAc)TSAP (where GalNAc is O-linked N-acetylgalactosamine), were shown to coelute following re

293 , composed mainly of galacturonic acid and N-acetylgalactosamine, were characterised for the first ti

294 ed on these results and the orientation of N-acetylgalactosamine when bound to an homologous galactos

295 , however, did not form 4, 6-di-O-sulfated N-acetylgalactosamine when chondroitin sulfate C was used

296 on Thr(402) with an N-acetylglucosamine or N-acetylgalactosamine, whereas Ser(692) remained unmodifie

297 , which inhibit membrane interactions, and N-acetylgalactosamine, which targets asialoglycoprotein re

298 red O-glycans consisting of Ser/Thr-linked N-acetylgalactosamine with beta1,3-linked galactose and va

299 ith UDP-glucose and interconversion of UDP-N-acetylgalactosamine with UDP-N-acetylglucosamine.

300 N-Acetylgalactosamine yielded two major peaks, which were